SLNO Q2 2017 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1,000-99.7% YoY

Gross Profit

-$41,000-4100.0% margin

Operating Income

-$3M-321000.0% margin

Net Income

-$4M-396600.0% margin

EPS (Diluted)

$-6.25

QoQ Revenue Growth

-99.6%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$443,000

Balance Sheet

Total Assets

$30M

Total Liabilities

$4M

Stockholders' Equity

$27M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1,000	$391,000	-99.7%
Gross Profit	-$41,000	-$37,000	-10.8%
Operating Income	-$3M	-$3M	+7.0%
Net Income	-$4M	-$4M	-12.9%